Delayed Diagnosis in Army Ranger Postdeployment Primaquine-Induced Methemoglobinemia
2019..
Presumptive antirelapse therapy (PART) with primaquine for Plasmodium vivax malaria postdeployment is an important component of the US military Force Health Protection plan. While primaquine is well tolerated in the majority of cases, we present a unique case of an active duty Army Ranger without glucose-6-phosphatase dehydrogenase or cytochrome b5 reductase (b5R) deficiencies who developed symptomatic methemoglobinemia while taking PART following a deployment to Afghanistan.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Journal of special operations medicine : a peer reviewed journal for SOF medical professionals - 19(2019), 3 vom: 01., Seite 14-16 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Essendrop, Robyn [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 22.10.2019 Date Revised 03.06.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.55460/CB3T-UBQV |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301474370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301474370 | ||
| 003 | DE-627 | ||
| 005 | 20231225104710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.55460/CB3T-UBQV |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1004.xml |
| 035 | |a (DE-627)NLM301474370 | ||
| 035 | |a (NLM)31539427 | ||
| 035 | |a (PII)CB3T-UBQV | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Essendrop, Robyn |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Delayed Diagnosis in Army Ranger Postdeployment Primaquine-Induced Methemoglobinemia |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.10.2019 | ||
| 500 | |a Date Revised 03.06.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a 2019. | ||
| 520 | |a Presumptive antirelapse therapy (PART) with primaquine for Plasmodium vivax malaria postdeployment is an important component of the US military Force Health Protection plan. While primaquine is well tolerated in the majority of cases, we present a unique case of an active duty Army Ranger without glucose-6-phosphatase dehydrogenase or cytochrome b5 reductase (b5R) deficiencies who developed symptomatic methemoglobinemia while taking PART following a deployment to Afghanistan | ||
| 650 | 4 | |a Case Reports | |
| 650 | 7 | |a Primaquine |2 NLM | |
| 650 | 7 | |a MVR3634GX1 |2 NLM | |
| 700 | 1 | |a Friedline, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Cruz, John |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of special operations medicine : a peer reviewed journal for SOF medical professionals |d 2009 |g 19(2019), 3 vom: 01., Seite 14-16 |w (DE-627)NLM191224561 |x 1553-9768 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2019 |g number:3 |g day:01 |g pages:14-16 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.55460/CB3T-UBQV |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2019 |e 3 |b 01 |h 14-16 | ||